-
Mashup Score: 2phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL - 11 month(s) ago
Key Points. Patients with DLBCL Richter transformation of CLL have a poor prognosis, especially if they have had prior BTKi exposure.Nivolumab and ibrutinib com
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Nivolumab and ibrutinib combination therapy is a safe and potential treatment option in patients with DLBCL Richter transformation. https://t.co/RCxu1mSNk2 #clinicaltrialsandobservations #immunobiologyandimmunotheraphy #lymphoidneoplasia https://t.co/RMS3WXguUO